Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stock
Alkem Laboratories is a Mumbai-headquartered integrated pharmaceutical company developing, manufacturing and marketing branded generics, generic medicines, APIs, nutraceuticals and biosimilars across India and international markets, with manufacturing and R&D assets in India and the USA and a significant biologics/CDMO capability developed via its Enzene subsidiary.
Q1 FY27 international sales were INR1,222 crore, up 16% year-on-year, with consolidated EBITDA margin of 20.5% and R&D at about 4% of revenue; net profit declined 21.7% year-on-year largely due to higher consolidated tax and some loss-making subsidiaries, highlighting profitable growth offset by one-off tax and consolidation effects.
Alkem is carrying near-term CDMO drag — roughly INR60 crore of quarterly operating expenses for its US CDMO — and management estimates an annualized USD25–30 million revenue run-rate is required to reach breakeven, with commercialization timing pushed into FY28 given project gestation and lumpiness of CDMO revenues.
The company is actively commercializing biosimilars: seven India biosimilars generate about INR150 crore annualized sales and Alkem launched Cetuxa globally; denosumab (Prolia) US approval missed goal date and is delayed by months, while some EU biologic launches are managed through partners such as Theramex.
Strategic M&A and capacity moves continue: Occlutech acquisition completed in July 2026 with a targeted ~INR400 crore revenue contribution for the year and US biomanufacturing facility plus EnzeneXT 2.0 commissioned in 2026, signalling a shift to scale biologics and connected manufacturing for international supply.
Pharmaceuticals & Biotechnology
Pharmaceuticals
59,366 Cr
Low Risk
26.9
35.2
2.0
4.3
5,933.00
4,879.85
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2205.00 | 62,231 Cr | 34.61 | 5.92 | 0.23 | 28.08 | 32.70 | 9.03 | ||
4965.15 | 59,366 Cr | 26.91 | 4.30 | 1.07 | 16.66 | 18.61 | 10.57 | ||
25744.40 | 54,707 Cr | 33.88 | 11.46 | 2.55 | 32.51 | 42.54 | 24.83 | ||
333.50 | 54,350 Cr | 130.52 | 1.58 | 0.15 | 1.14 | 3.64 | 0.65 | ||
1916.80 | 48,630 Cr | 35.25 | 6.03 | 0.31 | 14.15 | 18.58 | 11.15 | ||
2924.30 | 48,254 Cr | 42.75 | 4.66 | 0.68 | 9.92 | 14.02 | 9.02 | ||
2463.75 | 41,737 Cr | 39.07 | 18.41 | 2.31 | 45.69 | 61.23 | 24.70 | ||
| Median: 7 Co. | — | 2463.75 | 54,350 Cr | 35.25 | 5.92 | 0.68 | 16.66 | 18.61 | 10.57 |
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
3
Neutral
3
Bullish
8
Bearish
34
Neutral
3
Bullish
9
Bearish
31
Neutral
0
Bullish
1
Alkem Laboratories Ltd (ALKEM) is currently trading at 4,977.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alkem Laboratories is a Mumbai-headquartered integrated pharmaceutical company developing, manufacturing and marketing branded generics, generic medicines, APIs, nutraceuticals and biosimilars across India and international markets, with manufacturing and R&D assets in India and the USA and a significant biologics/CDMO capability developed via its Enzene subsidiary. Q1 FY27 international sales were INR1,222 crore, up 16% year-on-year, with consolidated EBITDA margin of 20.5% and R&D at about 4% of revenue; net profit declined 21.7% year-on-year largely due to higher consolidated tax and some loss-making subsidiaries, highlighting profitable growth offset by one-off tax and consolidation effects. Alkem is carrying near-term CDMO drag — roughly INR60 crore of quarterly operating expenses for its US CDMO — and management estimates an annualized USD25–30 million revenue run-rate is required to reach breakeven, with commercialization timing pushed into FY28 given project gestation and lumpiness of CDMO revenues. The company is actively commercializing biosimilars: seven India biosimilars generate about INR150 crore annualized sales and Alkem launched Cetuxa globally; denosumab (Prolia) US approval missed goal date and is delayed by months, while some EU biologic launches are managed through partners such as Theramex. Strategic M&A and capacity moves continue: Occlutech acquisition completed in July 2026 with a targeted ~INR400 crore revenue contribution for the year and US biomanufacturing facility plus EnzeneXT 2.0 commissioned in 2026, signalling a shift to scale biologics and connected manufacturing for international supply.
Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹4,879.85 and a high of ₹5,933.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alkem Laboratories Ltd has a market capitalization of approximately 59,365.82. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alkem Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 26.91 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 59,365.82 Cr, Alkem Laboratories Ltd is classified as a Mid Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alkem Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 26.91. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Alkem Laboratories’ 52nd AGM is scheduled for Thursday, 27 August 2026 at 11:00 AM IST, to be held via VC/OAVM.
Revenue from operations rose 11% YoY to ₹3,740 crore, while consolidated net profit fell to ₹520 crore from ₹664 crore in Q1 FY26.
The board approved the standalone and consolidated unaudited financial results at its meeting held on August 14, 2026.
Revenue from operations rose to about ₹3,740 crore, while consolidated net profit was reported at ₹520 crore versus ₹664 crore a year earlier.
